Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Adding Common Genetic Variants to Breast Cancer Risk Models Offers Only Small Benefit - (DGNews)
    TopAbstracts in Breast Cancer 03/16/2010 - (DGNews)
    Gene Test Receives Lukewarm Endorsement Into Breast Cancer Guidelines: Presented at NCCN - (DGDispatch)
    PET/CT Imaging Gets Cold Shoulder in Breast Cancer Guidelines: Presented at NCCN - (DGDispatch)
    Sentinel Node Biopsy Preferred in New Breast Cancer Guidelines: Presented at NCCN - (DGDispatch)

    News archive

     Recent webcasts/CME - Breast Cancer
    • Current Research on New Treatments for Patients With Difficult-to-Treat Advanced Breast Cancer: An Interactive Discussion of Challenges, Opportunities, and Practical Considerations
    • Overcoming Challenges in Difficult-to-Treat Advanced Breast Cancer: What Are the Latest Advances?
    • Overcoming Challenges in Difficult-to-Treat Advanced Breast Cancer: How to Apply the Evidence to Clinical Practice?
    • Patient Scenarios for Everyday Practice: Managing Advanced HER2-Positive Breast Cancer Throughout the Disease Continuum
    • Surgical Margins in Breast Conservation Therapy: How Much Should We Excise?

      Webcasts/CME archive

       Recent cases - Breast Cancer
        Solitary Adrenal Metastasis From Invasive Ductal Breast Cancer: An Uncommon Finding
        Metastatic Breast Cancer Deluding As A Papular Skin Rash
        Breast Pseudotumoral Radionecrosis as a Late Radiation-Induced Injury: A Case Report
        Large Family with Both Parents Affected by Distinct BRCA1 Mutations: Implications for Genetic Testing
        Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer

        Cases archive
          




        my personal edition > breast cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Exemestane May Help Downgrade Tumours Scheduled for Mastectomy to Breast-Conserving Surgery: Presented at EBCC

        By Paula Moyer

        NICE, FRANCE -- March 27, 2006 -- The aromatase inhibitor exemestane (Aromasin(R)) could make breast-conserving surgery possible in breast cancer patients with large hormone receptor-positive tumours who are scheduled for mastectomy, according to research presented here at the 5th European Breast Cancer Conference (EBCC).

        The findings show that neoadjuvant treatment with exemestane could shrink tumours in these patients, said principal investigator Hidefumi Takei, MD, consultant medical oncologist, division of breast surgery, Saitama Cancer Center, Saitama, Japan.

        In his presentation on March 23rd, Dr. Takei said his team was interested in exemestane's potential because earlier research had shown that other aromatase inhibitors could be used in the neoadjuvant setting for the purpose of shrinking the volume of operable tumours.

        In the multicentre, phase 2 Saitama Breast Cancer Clinical Study Group (SBCCSG) 03 trial, Dr. Takei and colleagues evaluated the efficacy and tolerability of neoadjuvant exemestane in 44 postmenopausal women with oestrogen receptor-positive tumours.

        Patients had tumours that were 3 cm or larger and were stage II to IIIB. Median patient age was 60 years (range 48 to 88 years).

        The study defined pathological response as grade 1b, 2, or 3, and clinical response was determined as being complete or partial by caliper, mammography, or ultrasound.

        Twenty-six patients had tumours that were stage IIA and 8 had stage IIB tumours. Of the remaining 10 patients, 4 had stage IIIA tumours and 6 had stage IIIB disease. Within this group, 32 had tumours that were positive for both oestrogen and progesterone receptors, and the remaining 12 were positive for oestrogen receptors and negative for progesterone receptors.

        All patients received 25 mg of exemestane daily for 4 months before surgery. In this group, 3 patients discontinued treatment due to adverse events, 1 each experienced a grade 3 haematological disorder, grade 2 dizziness, and grade 1 vaginal bleeding, respectively.

        Among the 41 treated patients, there were no complete responses, and 27 had a partial response, for an overall clinical response rate of 66%. Among the remaining patients, 22% had stable disease and 12% had progressive disease.

        Three patients went on to undergo chemotherapy due to disease progression. Eight patients refused surgery due to either a partial response or stable disease after treatment and continued on exemestane.

        In the 30 patients who had surgery but did not have chemotherapy, 93% were able to have breast-conserving surgery. Within the cohort of 30 patients, 43% had a pathological response.

        The investigators observed a response of grade 1b in 9 patients and grade 2 in 4 patients.

        Aromasin is manufactured by Pfizer.


        [Presentation: Multicenter Phase II Trial of Neoadjuvant Exemestane for Postmenopausal Patients With Hormone-Sensitive, Operable Breast Cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Abstract 386]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send